Retatrutide (LY-3437943) is an investigational drug developed by Eli Lilly that acts as a triple hormone receptor agonist : GLP-1 (glucagon-like peptide-1) receptor agonist GIP (glucose-dependent insulinotropic polypeptide) receptor agonist Glucagon receptor agonist - read about why this is so important here This triagonist approach amplifies the metabolic impact seen with GLP-1 and GIP combinations like tirzepatide, while also leveraging glucagons thermogenic and energy-expending properties
Protocols do not run forever
5.1.2 Effects on pancreatic -cell glucagon release In addition to their insulinotropic effects on -cells, both GIP and GLP-1 play a role in regulating glucagon secretion of pancreatic -cells, with GIP increasing and GLP-1 suppressing glucagon secretion, both in a glucose-dependent manner
GLP-1 receptor agonists such as semaglutide (Ozempic), tirzepatide (Mounjaro, Zepbound), and liraglutide (Victoza) are advanced medical versions of a hormone your gut produces
Load more Close Code Verified by our community Get 25% Off Lose Weight Quiz (Promo Code) Details 11 verifications Offer's Details: Save 25% on your purchase with this special Noom discount
